ライフサイエンスコーパス: proto-oncogene

1 ative transcription factor may also act as a proto-oncogene.

2 emia through aberrant expression of the EVI1 proto-oncogene.

3 F2alpha regulation is JNK dependent, via jun proto-oncogene.

4 lowing for quantitative analysis of the cMYC proto-oncogene.

5 inhibitors, and overexpression of the c-Myc proto-oncogene.

6 the estrogen receptor coregulator PELP1 is a proto-oncogene.

7 has previously been described as a powerful proto-oncogene.

8 r and therefore generally considered to be a proto-oncogene.

9 t into the categorization of ECT2 as a human proto-oncogene.

10 ss mRNAs including the mRNA encoding the Mos proto-oncogene.

11 he translocation and the deregulation of the proto-oncogene.

12 quently associated with mutations to the RET proto-oncogene.

13 cations between a tissue-specific gene and a proto-oncogene.

14 s a member of Fos gene family and is a known proto-oncogene.

15 oglobulin heavy-chain transcription and as a proto-oncogene.

16 n epidermal growth factor receptor 2 [HER2]) proto-oncogene.

17 r the transcriptional expression of the cMet proto-oncogene.

18 by the activated oncogene compared with the proto-oncogene.

19 ose expression mimics that of the nearby MYC proto-oncogene.

20 ssor genes, restrict the activity of the Src proto-oncogene.

21 isk region physically interacts with the MYC proto-oncogene.

22 ene homolog (Kras), or overexpression of MYC proto-oncogene.

23 h splicing factor 3 (SRSF3 or SRp20) being a proto-oncogene.

24 gulation, like P53 tumor suppressor and cMYC proto-oncogene.

25 GCM2, suggesting that GCM2 is a parathyroid proto-oncogene.

26 in the rearranged during transfection (RET) proto-oncogene.

27 ain of specific genomic loci known to harbor proto-oncogenes.

28 activate tumor suppressor genes and activate proto-oncogenes.

29 factor activity of the NOTCH1, MYC, and IRF4 proto-oncogenes.

30 k of transcription factors including several proto-oncogenes.

31 owths due to vector insertion near or within proto-oncogenes.

32 onmalignant cells was sufficient to activate proto-oncogenes.

33 ted neighborhoods containing prominent T-ALL proto-oncogenes.

34 druplex structures are found in promoters of proto-oncogenes.

35 sting and is then inhibited by thymoma viral proto-oncogene 1 (Akt) after feeding.

36 e closely linked E26 transformation-specific proto-oncogene 1 (ETS1) is overexpressed in these FLI1-d

37 stic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung c

38 h pathways dependent or not dependent on ABL proto-oncogene 1 non-receptor tyrosine kinase (c-Abl).

39 ncided with a 4.5-fold increase in ETS1 (ETS proto-oncogene 1) mRNA, suggesting that ETS1 is involved

40 tibody and a breakpoint cluster region - ABL proto-oncogene 1, nonreceptor tyrosine kinase (BCR-ABL1)

41 The RET proto-oncogene, a tyrosine kinase receptor, is widely kn

42 Activity of the proto-oncogene ABL1 is upregulated in FH-deficient kidne

43 gammaretrovirus vectors have caused cellular proto-oncogene activation and leukemia, necessitating th

44 om an index patient and demonstrate that MET proto-oncogene activation is important for tumor growth

45 Here we report that the proto-oncogene Akt-3/PKBgamma (Akt3) phosphorylates Argo

46 tidyl inositol 3 kinase (PI3K)-thymoma viral proto-oncogene (AKT) inhibitors to kill tumor cells.

47 regulated kinase (ERK) and the thymoma viral proto-oncogene (Akt), followed by activation of the mamm

48 ocess that we hypothesized involved c-met, a proto-oncogene amplified in breast tumors that promotes

49 ts in this tumour, including one in the KRAS proto-oncogene and 391 others in coding regions, as well

50 are cell cycle regulators and function as a proto-oncogene and a tumor suppressor respectively in hu

51 e multifunctional signal transducer Ras is a proto-oncogene and frequently becomes mutated in a varie

52 The proto-oncogene and inhibitor of protein phosphatase 2A (

53 The Skp2 E3-ubiquitin ligase can act as a proto-oncogene and its aberrant overexpression is freque

54 esults therefore identify miR-22 as a potent proto-oncogene and suggest that aberrations in the miR-2

55 is study shows that Erk1 can be considered a proto-oncogene and that Erk molecules possess unusual au

56 Mutations in the RET proto-oncogene and vascular endothelial growth factor re

57 Ecotropic viral integration site 1 (EVI1), a proto-oncogene and zinc finger transcription factor, pla

58 ed by numerous common integration sites near proto-oncogenes and by increased abundance of clones wit

59 gration of therapeutic vectors has activated proto-oncogenes and contributed to leukemia.

60 scription factor genes, including MYC family proto-oncogenes and neuroendocrine lineage-specific fact

61 e p53 mutations or undergo amplifications of proto-oncogenes and receptor tyrosine kinases, implicati

62 n-protein interactions, including binding to proto-oncogenes and tumor suppressors to regulate cell d

63 reaks and enhances the mutation frequency of proto-oncogenes and tumor suppressors.

64 tion of caspase-1 via over-expression of the proto-oncogene (and early osteoblast factor) Ets-1.

65 tor of activated T cells 3 (NFATc3) and FosB proto-oncogene, AP-1 transcription factor subunit (FosB)

66 Mutations or amplification of the MET proto-oncogene are involved in the pathogenesis of sever

67 to constitutive activation of NRAS and KRAS proto-oncogenes are among the most common in human cance

68 In contrast, the Hras proto-oncogene attenuated the activity of mutant Kras in

69 located near the Casitas B-lineage lymphoma proto-oncogene b gene (CBLB).

70 Twenty-six patients were tested for a proto-oncogene B-Raf (V600E) (BRAF) mutation (18 had the

71 directly activated the transcription of the proto-oncogene BCL6 in normal germinal-center (GC) B cel

72 core Sgamma1 region into the first intron of proto-oncogene Bcl6, which is a non-Ig target of SHM.

73 und that a key transcriptional repressor and proto-oncogene, Bcl6 is significantly down-regulated in

74 ng is often considered a model hematopoietic proto-oncogene because of its role as the main trigger o

75 Although the Rgr proto-oncogene belongs to the RalGDS family of guanine n

76 isms that prevent proteasomal degradation of proto-oncogene beta-catenin (CTNNB1) and its eventual tr

77 s the Wnt-signaling pathway by targeting the proto-oncogene beta-catenin for destruction by cytoplasm

78 The polycomb complex proto-oncogene BMI1 [B lymphoma Mo-MLV insertion region

79 ing pathway, directed by the oncogenic B-Raf proto-oncogene (BRAF) variant BRAF(V600E), that mediates

80 y displays mutational activation of the KRAS proto-oncogene but, unlike lung cancers expressing mutat

81 shown to be negatively modulated by the MYCN proto-oncogene, but the mechanism of repression was uncl

82 , activation of otherwise normally repressed proto-oncogenes by promoter demethylation has been infre

83 d ATM-dependent signalling, and identify the proto-oncogene c-Abl as a mediator of this modification.

84 The proto-oncogene c-fms, whose 3'untranslated region (3'UTR

85 e shown that co-expression of TAp73 with the proto-oncogene c-Jun can augment cellular growth and pot

86 rrelation between GAPDH upregulation and the proto-oncogene c-jun expression (r = 0.543, P = .003).

87 The proto-oncogene c-Jun is a component of activator protein

88 Previously, we have shown that the bZIP proto-oncogene c-Maf regulates expression of alphaA-crys

89 ivity requires binding to its receptors, the proto-oncogene c-Met and heparan sulfate proteoglycan (H

90 oticed transcriptional repression of 5-LO by proto-oncogene c-Myb and conclude that loss of stromal 5

91 egulated at the transcriptional level by the proto-oncogene c-Myb and is required for c-Myb-induced p

92 Subsequently, upregulation of proto-oncogene c-Myb in TAMs induced a stable transcript

93 blocked at the polymorphic site and that the proto-oncogene c-MYB modulates the release of the pausin

94 The 5' untranslated region of the proto-oncogene c-myc contains an internal ribosome entry

95 reconstructed in cell culture, and that the proto-oncogene c-Myc controls the generation of self-ren

96 The proto-oncogene c-Myc encodes a transcription factor that

97 We have previously demonstrated that the proto-oncogene c-Myc is essential for all the phenotypes

98 Inappropriate expression of the proto-oncogene c-Myc is known to cause DNA damage.

99 The proto-oncogene c-Myc paradoxically activates both prolif

100 Here we show that the proto-oncogene C-Raf paradoxically inhibits B-Raf(V600E)

101 ed sensitivity to dasatinib by targeting the proto-oncogene c-SRC.

102 sociated with the binding of Imatinib to the proto-oncogene c-Src.

103 MR) status and somatic mutation in the B-Raf proto-oncogene (c.1799T>A [V600E]; BRAFV600E) or exon 2

104 The proto-oncogene, c-MYC, which declines during SynT differ

105 AnxA2 and SOX2 bind to proto-oncogenes, c-Myc and c-Src, and AnxA2 forms a func

106 ve established that amplification of the MET proto-oncogene can cause resistance to epidermal growth

107 Numerous kinase pathways and products of proto-oncogenes can up-regulate Pol I, whereas tumor sup

108 The proto-oncogene Casitas b-lineage lymphoma (c-Cbl) is an

109 Activating mutations in the RET proto-oncogene cause hereditary MTC, which provides a st

110 For example, the human KRAS proto-oncogene contains a nuclease-hypersensitive elemen

111 viral vectors, but insertional activation of proto-oncogenes contributed to leukemia in some patients

112 ied novel direct targets, including CRK-like proto-oncogene (CRKL) and focal adhesion kinase (FAK).

113 Levels of the proto-oncogene Cyclin D1 are reduced in Gli1(null) mice

114 sion in association with mRNAs encoding many proto-oncogenes, cytokines, chemokines, and proinflammat

115 Bcl3 is a putative proto-oncogene deregulated in hematopoietic and solid tu

116 e runt-related transcription factor 1, Fli-1 proto-oncogene, E-twenty-six (ETS) transcription factor

117 PTTG1-dependent expression of the RhoGEF proto-oncogene ECT2 was observed in a number of ccRCC ce

118 The MLL (mixed-lineage leukemia) proto-oncogene encodes a histone methyltransferase that

119 The c-abl proto-oncogene encodes a nonreceptor tyrosine kinase inv

120 The RET (rearranged during transfection) proto-oncogene encodes a receptor tyrosine kinase for me

121 RET proto-oncogene encodes a receptor tyrosine kinase whose

122 The human REL proto-oncogene encodes a transcription factor in the nuc

123 The Myb proto-oncogene encodes a transcription factor required d

124 The BCL6 proto-oncogene encodes a transcriptional repressor that

125 The BCL6 proto-oncogene encodes a transcriptional repressor that

126 The c-fes proto-oncogene encodes a unique nonreceptor protein-tyro

127 The c-abl proto-oncogene encodes a unique protein-tyrosine kinase

128 showed that miR-155 is coexpressed with the proto-oncogene encoding c-MYC in positively selected B c

129 mammary carcinoma cells that overexpress the proto-oncogene Erbb2 (also known as Neu), which is frequ

130 The proto-oncogenes ETV1, ETV4 and ETV5 encode transcription

131 The proto-oncogene EVI1 (ecotropic viral integration site-1)

132 human androgen receptor (AR) coactivator and proto-oncogene expressed at low levels in normal human r

133 Vav1 is a proto-oncogene expressed in hematopoietic cells that is

134 epidermal growth factor (EGF)-induced c-FOS proto-oncogene expression in mammalian cells.

135 this method by examining copy number in the proto-oncogene FLT3 and the common V600E point mutation

136 e resulted in an increased expression of the proto-oncogenes FOS and JUN in both cell lines at 72 hr.

137 rough a series of studies, we identified the proto-oncogene fosab (cfos) as a potent miR-101a target

138 Mixed-lineage leukemia (MLL) is a proto-oncogene frequently involved in chromosomal transl

139 Although discovered as the proto-oncogene from which the Abelson leukemia virus der

140 es associated with breast cancer can control proto-oncogene function.

141 Because proto-oncogenes function as key negative regulators of t

142 In the skin, the Kras proto-oncogene functions cooperatively with mutant Hras

143 Here, we demonstrate that the proto-oncogene fused in sarcoma (FUS), the chromatin rem

144 on of the growth factor independent 1 family proto-oncogenes, GFI1 and GFI1B.

145 cellular apoptosis; we also showed that the proto-oncogene H-Ras becomes activated in these cells un

146 The RAS proto-oncogene Harvey rat sarcoma viral oncogene homolog

147 The Myc proto-oncogene has been intensively studied in tumorigen

148 e discovery of potent inhibitors of the BRAF proto-oncogene has revolutionized therapy for melanoma h

149 direct pharmacological inhibition of the RAS proto-oncogene has thus far been unsuccessful, we explor

150 binger DNA transposons carrying the Myb-like proto-oncogene have expanded dramatically in the Pleurod

151 miR-221 and miR-222, upregulated by the MET proto-oncogene, have been already described to enhance c

152 Similar to c-myc, amplification of the proto-oncogene HER2/neu occurs in 10%-30% of breast canc

153 alpha leads to derepression of the embryonal proto-oncogene Hmga2 in Nkx2-1-negative tumors.

154 nvadopodia component Tks5long, the embryonal proto-oncogene Hmga2, and the epithelial-to-mesenchymal

155 xpression of the shorter mRNA isoform of the proto-oncogene IGF2BP1/IMP-1 led to far more oncogenic t

156 BCL6 is the product of a proto-oncogene implicated in the pathogenesis of human B

157 nslation of the mixed lineage leukemia (MLL) proto-oncogene in an arginine methylation-dependent mann

158 dies establish an essential role of the Pbx1 proto-oncogene in corneal morphogenesis.

159 Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may cons

160 eased copy number and expression of the PIM1 proto-oncogene in genomic data sets of patients with TNB

161 a mechanism by which lncRNA MALAT1 acts as a proto-oncogene in hepatocellular carcinoma, modulating o

162 conventional ErbB2 ones expressing the erbB2 proto-oncogene in mammary epithelium.

163 w mechanistic insights into the role of this proto-oncogene in stem cell differentiation, neuronal ag

164 Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas provide therapeut

165 genic mice overexpressing the Neu/Her2/ERBB2 proto-oncogene in the mammary gland.

166 is for discovery of epigenetically activated proto-oncogenes in head and neck cancer tumors.

167 gs to the most frequent aberrantly expressed proto-oncogenes in human acute leukemias and is highly l

168 nsertions of AAV serotype 2 seem to activate proto-oncogenes in human hepatocellular carcinoma.

169 er cancer development induced by AKT and Ras proto-oncogenes in mice.

170 sites within LMO2, MECOM, and other lymphoid proto-oncogenes in our patients.

171 bacteria integrating into the 5'-UTR of four proto-oncogenes in stomach cancer sequencing data.

172 domain-containing 7 (Fbw7) degrades several proto-oncogenes including c-Myc, cyclinE, Notch1, and c-

173 d transcriptional activation of a network of proto-oncogenes, including Erg, Flt3, Lmo2, Myb, and Sox

174 Lastly, we identified several new proto-oncogenes, including Foxr2 (encoding forkhead box

175 Most transcription of the MYC proto-oncogene initiates in the near upstream promoter,

176 r BRCA1-deficient MBC by introducing the MET proto-oncogene into a BRCA1-associated breast cancer mod

177 as originally identified as the product of a proto-oncogene involved in chromosomal translocations in

178 expression strongly correlates with c-jun, a proto-oncogene involved in liver tumorigenesis in human

179 ox R2), which we functionally validated as a proto-oncogene involved in MPNST maintenance.

180 The MYCN proto-oncogene is amplified in a number of advanced-stag

181 Overexpression of the c-Myc proto-oncogene is associated with a broad spectrum of hu

182 Expression of the MECOM (also known as EVI1) proto-oncogene is deregulated by chromosomal translocati

183 Somatic activation of the KRAS proto-oncogene is evident in almost all pancreatic cance

184 The KRAS proto-oncogene is mutated in >90% of PDAC.

185 mplification and overexpression of erbB2/neu proto-oncogene is observed in 20-30% human breast cancer

186 The MET proto-oncogene is primarily linked to tumor metastasis,

187 enome has recently disclosed that the NOTCH1 proto-oncogene is recurrently mutated at CLL presentatio

188 The MYC proto-oncogene is upregulated, often at the transcriptio

189 ell leukemia 1 (TCL1), the AKT modulator and proto-oncogene, is differentially expressed in CLL and l

190 c-Jun, the first cellular proto-oncogene, is overexpressed in human breast cancer.

191 the Drosophila homologue of the human c-myc proto-oncogene, is regulated in vitro and in vivo by mem

192 30 (involved in membrane transport), and the proto-oncogene JUN, indicate that the Rab1b increase act

193 e transcription factor c-Jun, product of the proto-oncogene JUN, is a key regulator of mitochondrial

194 ents FBJ osteosarcoma oncogene (FOS) and jun proto-oncogene (JUN) to the promoters of a subset of Tol

195 Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal

196 The proto-oncogene KRAS is mutated in a wide array of human

197 RasG, which are highly related to the human proto-oncogene KRas.

198 >A [V600E]; BRAFV600E) or exon 2 of the KRAS proto-oncogene (KRAS) in the primary tumor with SAR in p

199 mutations in the RET (formerly MEN2A, MEN2B) proto-oncogene located on chromosomal band 10q11.21.

200 rms a long-range chromatin loop with the MYC proto-oncogene located several hundred kilobases telomer

201 The LYN proto-oncogene (LYN) is required for signaling in both d

202 iption factor binding to the promoter of the proto-oncogene MDM2, and to influence cancer risk.

203 BBB permeability in part because Src kinase proto-oncogene members stimulate proliferation of newbor

204 signaling uses lateral activation of the met proto-oncogene (MET) through SRC proto-oncogene nonrecep

205 The MET proto-oncogene (MET) tyrosine kinase receptor promotes m

206 iously identified HuR as a promoter of c-fms proto-oncogene mRNA.

207 These include the signaling gene TGFBR1, the proto-oncogene MYB as well as many immune-related genes

208 ion between the expression of TOP1MT and the proto-oncogene MYC (c-myc).

209 strong, haplotype-specific activation of the proto-oncogene MYC by the integrated HPV-18 genome appro

210 Tumour suppressor p53 or proto-oncogene MYC is frequently altered in squamous car

211 ell cycle using the physiologically relevant proto-oncogene MYC to drive cell cycle re-entry.

212 The c-MYC proto-oncogene (MYC) is a direct target of beta-catenin/

213 While the c-Myc proto-oncogene (Myc) is required for intestinal phenotyp

214 pt levels of multiple genes, focusing on the proto-oncogene, MYC.

215 The proto-oncogene MYCN is mis-expressed in various types of

216 regulation of proliferation mediated by the proto-oncogene N-Myc.

217 ated ITG-dependent focal adhesion kinase/Src proto-oncogene non-receptor tyrosine kinase signaling.

218 uter mitochondrial membrane 34) and SRC (SRC proto-oncogene, non-receptor tyrosine kinase).

219 of the met proto-oncogene (MET) through SRC proto-oncogene nonreceptor tyrosine kinase to maximize c

220 The proto-oncogenes NTRK1/2/3 encode the tropomyosin recepto

221 lated neighborhoods, we investigated whether proto-oncogenes occur within these structures and whethe

222 Myc is a proto-oncogene often found to be deregulated in many can

223 i-novel protein) was discovered as a nuclear proto-oncogene on the basis of its ability to induce tra

224 n be caused by germline mutations of the RET proto-oncogene or occurs as a sporadic form.

225 en initiated by genetic events that activate proto-oncogenes or inactivate tumor-suppressor genes.

226 a biophysical characterization of the c-MYC proto-oncogene P1 promoter quadruplex and its interactio

227 dence upon, the hepatocyte growth factor/met proto-oncogene pathway.

228 The proto-oncogene PIK3CA has been well studied for its acti

229 Here, we identify the protein kinase and proto-oncogene PIM3 as being repressed downstream of mTO

230 ayed highly significant up-regulation of the proto-oncogene pleomorphic adenoma gene 1 (PLAG1), sugge

231 ver, whether the human mTOR gene itself is a proto-oncogene possessing tumorigenicity has not been fi

232 guingly, YccA is a functional homolog of the proto-oncogene product Bax Inhibitor-1, which may share

233 We propose that combined control of proto-oncogene product levels and proteins involved in D

234 SF) and its receptor, the product of the MET proto-oncogene, promote invasion and metastasis of tumor

235 pe was observed by overexpressing c-Myc (Myc proto-oncogene protein), a downstream target of Pim kina

236 The proto-oncogene PTTG and its binding partner PBF have bee

237 el in Drosophila, oncogenic mutations of the proto-oncogene Ras (Ras(V12)) maintain tumorous cells in

238 wth factor (HGF) acting through its specific proto-oncogene receptor c-Met has been suggested to play

239 nfluences the prognostic significance of KIT proto-oncogene receptor tyrosine kinase (KIT) and platel

240 IRF-4 was originally identified as a proto-oncogene resulting from a t(6;14) chromosomal tran

241 , with the most frequent variants in the ret proto-oncogene (RET).

242 the identification of clients, such as Raf-1 proto-oncogene, Ser/Thr kinase (RAF1), that are particul

243 The B-Raf proto-oncogene serine/threonine kinase (BRAF) gene is th

244 ard, which in turn gradually suppressed RAF1 proto-oncogene serine/threonine kinase (RAF1)/ERK signal

245 Here, we report the efficacy of the Raf proto-oncogene serine/threonine protein kinase (RAF) inh

246 ted HRAS(G12V) with its effector protein RAF proto-oncogene serine/threonine protein kinase 1 (RAF1).

247 inst unrelated protein kinases; however, the proto-oncogene serine/threonine protein kinase PIM1 (PIM

248 The protein kinase B-Raf proto-oncogene, serine/threonine kinase (BRAF) is an onc

249 errant HGF-MET (hepatocyte growth factor-met proto-oncogene) signaling activation via interactions wi

250 a mechanism that involves downregulation of proto-oncogene signals.

251 variation in ten individuals with SGS in the proto-oncogene SKI, a known repressor of TGF-beta activi

252 bited antifibrotic Sloan-Kettering Institute proto-oncogene (Ski) and Ski-related novel gene, non-Alu

253 The proto-oncogene Smoothened (Smo) is a key transducer of t

254 Consistent with a role as proto-oncogene, SnoN negatively regulates TGF-beta signa

255 knockout technology, we disrupted the c-myb proto-oncogene specifically in adult bone marrow (BM) to

256 We showed that proto-oncogene Src kinase and Akt are direct targets of

257 ing enzyme, PIPKIgammai2, functions with the proto-oncogene Src, to regulate oncogenic signaling.

258 owth of tumor cells in coordination with the proto-oncogene Src.

259 eport that the RNA-binding protein (RBP) and proto-oncogene SRSF1 (serine and arginine-rich splicing

260 a hallmark of KS by unique activation of the proto-oncogene STAT3, coupled with MK2-mediated inactiva

261 errantly expressed both stem cell-associated proto-oncogenes, such as Lmo2, Hhex, Lyl1, and Kit, whic

262 For example, the proto-oncogene SYK is upregulated in retinoblastoma and

263 The small GTPase H-Ras is a proto-oncogene that activates a variety of different pat

264 MET is a known proto-oncogene that acts through a diverse set of signal

265 53 with a gain of function (GOF), creating a proto-oncogene that contributes to tumorigenesis, tumor

266 Together, we conclude that eIF3i is a proto-oncogene that drives colon oncogenesis by translat

267 PIKE-A, a proto-oncogene that is one of the important components o

268 ge of Mer tyrosine receptor kinase (MerTK, a proto-oncogene that plays a critical role in phagocytosi

269 oinositide 3-kinase enhancer A (PIKE-A) is a proto-oncogene that promotes tumor growth and transforma

270 as-like DNA in the 5'-UTR and 3'-UTR of four proto-oncogenes that are up-regulated in their transcrip

271 ascribed to PDAC with mutations in the KRAS2 proto-oncogene thought to be an early event in the progr

272 ed in hepatocellular carcinoma and acts as a proto-oncogene through Wnt pathway activation and induct

273 several cancer/testis antigens and the c-kit proto-oncogene throughout multiple recurrences.

274 e is known about how the transformation from proto-oncogene to activated oncogene drives the expressi

275 f escape whereby tumor cells upregulated the proto-oncogene transcriptional regulators c-MYC and YAP1

276 Aberrant expression of BCL11B or proto-oncogene translocation to the vicinity of BCL11B c

277 d a novel oncogenic fusion involving the MER proto-oncogene tyrosine kinase (MERTK) and discovered a

278 C-MER proto-oncogene tyrosine kinase (MERTK) is a receptor tyr

279 hagocytosis due to a deficiency of the c-Mer proto-oncogene tyrosine kinase (Mertk) nonetheless conta

280 We now show that signaling through the Mer proto-oncogene tyrosine kinase (MerTK) receptor in cultu

281 Other studies have shown elevated proto-oncogene tyrosine kinase (SRC) activity in invasiv

282 eptor antagonists atrasentan and zibotentan, proto-oncogene tyrosine-protein kinase (SRC) inhibitor d

283 Proto-oncogene tyrosine-protein kinase (Src) was identif

284 (miR200c, miR20b, and miR31through cellular proto-oncogene tyrosine-protein kinase Src (cSrc)), resp

285 phorylated by the tyrosine kinases p60c-Src (proto-oncogene tyrosine-protein kinase) and the proline-

286 ng that the HER2 oncogene, as opposed to the proto-oncogene, upregulates expression of the E2F2 trans

287 Here the activity of the proto-oncogene Vav2, a GEF for Rac1, RhoA, and Cdc42, is

288 in leukemogenesis by causing deregulation of proto-oncogenes via relocation of cryptic regulatory DNA

289 3-14 region, and more specifically, the CDK4 proto-oncogene was highly amplified.

290 Expression of the c-Myc proto-oncogene was increased in proliferating cytotropho

291 ABL1 is a proto-oncogene well known as part of the fusion gene BCR

292 The MYC proto-oncogene, which encodes a master transcriptional r

293 hat it is cleaved and interacts with the JUN proto-oncogene, which forms part of the activator protei

294 Recent data suggest that the MYB proto-oncogene, which is an important regulator of hemat

295 emonstrate that overexpression of eIF4E, the proto-oncogene whose activity is specifically inhibited

296 These results suggest that MAGE-A11 is a proto-oncogene whose increased expression in prostate ca

297 ous studies have demonstrated that CREB is a proto-oncogene whose overexpression promotes cellular pr

298 rentiation, and were established early on as proto-oncogenes, with aberrant expression linked to tumo

299 r matrix and elevated expression of specific proto-oncogenes within the adjacent epithelium represent

300 evious results, we hypothesized that the MYC proto-oncogene would show differential expression in pRC